How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Want to cut your energy bills? Here’s how five experts are doing it 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
DURHAM, N.C., March 17, 2016 -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the company will participate in the Alliance for Regenerative Medicine Cell and Gene Therapy Investor Day to be held March 22, 2016 at the Metropolitan Club in New York City.
Jeffrey D. Abbey, president and chief executive officer of Argos, will present an update on the company’s clinical development programs at 11:30am ET in the main bar room. For more information visit http://arminvestorday.com/agenda/.
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of HIV, which is currently being evaluated in a phase 2 clinical trial aimed at HIV eradication in adult patients.
Forward-Looking Statements
Any statements in this press release about Argos’ future expectations, plans and prospects, including statements about the expected and potential future closings of the private placement, Argos’ financial prospects, anticipated use of proceeds, future operations and sufficiency of funds for future operations, clinical development of Argos’ product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for Argos and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," “may,” "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the conditions for the potential future closings of the private placement will be satisfied; whether Argos' cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Argos' product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos’ Form 10-Q for the quarter ended September 30, 2015, which is on file with the SEC, and in other filings Argos makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Argos’ views as of the date hereof. Argos anticipates that subsequent events and developments will cause Argos’ views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos’ views as of any date subsequent to the date hereof.
Investor Contact: John Menditto Argos Therapeutics, Inc. 919-908-0687 [email protected] Media Contact: Adam Daley Berry & Company Public Relations 212-253-8881 [email protected]
